This inventor holds 6 USPTO granted patents and 12 published patent applications, plus 4 CIPO patents and 6 EPO patents. Top assignees: The University of Chicago, Anokion Sa. Active years: 2025-2026.
Company Filing History:
6 out of 964 
2 out of 6 Years Active: 2025-2026
Title: Jeffrey A Hubbell: Innovator in Immunotherapy
Introduction
Jeffrey A Hubbell is a prominent inventor based in Chicago, IL (US). He has made significant contributions to the field of immunotherapy, holding 6 patents that focus on innovative methods and compositions for treating immune responses and cancer.
Latest Patents
Hubbell's latest patents include "Compositions and methods concerning immune tolerance," which provides compositions comprising mannose-fused antigens to target mannose receptors. These compositions are designed to prevent immunity or reduce an immune response to protein-based drugs that would otherwise elicit such responses. Another notable patent is "Methods and compositions for treating cancer with ECM-affinity peptides linked to cytokines." This patent addresses the need for targeted therapies by providing compositions that limit systemic exposure and reduce side effects, specifically targeting cytokines to the tumor environment.
Career Highlights
Throughout his career, Jeffrey A Hubbell has worked with esteemed institutions such as the University of Chicago and Anokion SA. His work has significantly advanced the understanding and treatment of immune-related conditions and cancer therapies.
Collaborations
Hubbell has collaborated with notable individuals in his field, including Jun Ishihara and Ako Ishihara. These collaborations have contributed to the development of innovative solutions in immunotherapy.
Conclusion
Jeffrey A Hubbell's contributions to immunotherapy through his patents and collaborations highlight his role as a leading inventor in the field. His work continues to influence advancements in medical treatments and therapies.